Hospital
Riverside Medical Center
Riverside Medical Center was paid $9.32M by Medicaid between Jan 2018 and Dec 2024, across 146 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoRIVERSIDE MEDICAL CENTER
FRANKLINTON, LA 70438
FRANKLINTON, LA 70438
33aNPI1700874062assigned 10/11/2005
33bProvider typeCritical Access Hospital
28Total paid$9.32M
24GClaims289,604
24DCodes billed146
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#5 of 40
Median peer was paid$3.19M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,966 | $966K | |
| 2019 | 31,298 | $887K | |
| 2020 | 28,430 | $679K | |
| 2021 | 43,393 | $1.31M | |
| 2022 | 59,297 | $1.88M | |
| 2023 | 61,767 | $2.13M | |
| 2024incomplete | 42,453 | $1.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 14,177 | 12,790 | $2.78M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 20,474 | 18,347 | $2.18M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 3,811 | 3,309 | $908K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 11,524 | 9,954 | $391K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.3% | 25,297 | 10,867 | $311K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 2,535 | 2,257 | $220K |
| 71045 | Radiologic examination, chest; single view | 2.3% | 4,892 | 4,193 | $215K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 6,225 | 4,954 | $183K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 803 | 694 | $176K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 942 | 454 | $118K |
| 80053 | Comprehensive metabolic panel | 1.1% | 17,692 | 14,417 | $105K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 112 | 94 | $104K |
134 more codes
| 80050 | General health panel | 1.1% | 2,515 | $102K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,477 | $89K |
| 86403 | <1% | 8,039 | $73K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 698 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 728 | $71K |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,743 | $69K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,189 | $67K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,204 | $67K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,570 | $67K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,644 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 886 | $54K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,112 | $52K |
| 80061 | Lipid panel | <1% | 4,820 | $47K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 86 | $44K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 411 | $43K |
| 83735 | <1% | 9,708 | $37K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 78 | $34K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,437 | $33K |
| 84484 | <1% | 5,321 | $32K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 188 | $32K |
| 83880 | <1% | 1,815 | $31K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 19,395 | $30K |
| 82607 | <1% | 2,189 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,266 | $22K |
| 76830 | Ultrasound, transvaginal | <1% | 113 | $21K |
| 81001 | <1% | 8,867 | $18K | |
| 84466 | <1% | 1,872 | $17K | |
| 94664 | <1% | 945 | $15K | |
| 84703 | <1% | 2,319 | $15K | |
| 82553 | <1% | 2,870 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 161 | $14K |
| 82550 | <1% | 4,304 | $13K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 547 | $13K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 676 | $13K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 188 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,239 | $12K |
| 84439 | <1% | 1,738 | $12K | |
| 87186 | <1% | 1,429 | $11K | |
| 87070 | <1% | 1,455 | $11K | |
| 87077 | <1% | 1,130 | $9K | |
| 83540 | <1% | 1,906 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,074 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,236 | $8K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 42 | $8K |
| 85379 | <1% | 1,140 | $7K | |
| 87210 | <1% | 1,425 | $6K | |
| 93017 | <1% | 104 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 874 | $6K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 268 | $6K |
| 82728 | <1% | 755 | $6K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 95 | $5K |
| 87420 | <1% | 473 | $5K | |
| 84145 | <1% | 372 | $5K | |
| 83690 | <1% | 1,192 | $5K | |
| 85730 | <1% | 1,688 | $5K | |
| 87807 | <1% | 382 | $4K | |
| 85610 | <1% | 2,030 | $4K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 76 | $4K |
| 82746 | <1% | 408 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $3K |
| 82043 | <1% | 630 | $3K | |
| 83525 | <1% | 313 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 134 | $3K |
| 81003 | <1% | 1,739 | $3K | |
| 83704 | <1% | 208 | $3K | |
| 80074 | <1% | 56 | $2K | |
| 84144 | <1% | 108 | $2K | |
| 84480 | <1% | 294 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 624 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 190 | $1K |
| 87040 | <1% | 280 | $1K | |
| 83605 | <1% | 245 | $1K | |
| 73130 | <1% | 14 | $1K | |
| 90686 | <1% | 122 | $1K | |
| 73630 | <1% | 17 | $1K | |
| 93925 | <1% | 49 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 216 | $959.79 |
| 86592 | <1% | 231 | $899.25 | |
| 82948 | <1% | 366 | $827.52 | |
| 84403 | <1% | 32 | $722.68 | |
| 84402 | <1% | 32 | $713.16 | |
| 93922 | <1% | 94 | $643.82 | |
| 86480 | <1% | 13 | $619.80 | |
| 0003A | <1% | 13 | $612.04 | |
| 84481 | <1% | 40 | $537.20 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 12 | $473.70 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 33 | $416.13 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 43 | $368.16 |
| 82670 | <1% | 17 | $363.22 | |
| 86140 | <1% | 100 | $331.53 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $308.52 |
| 82626 | <1% | 12 | $303.24 | |
| 82627 | <1% | 13 | $288.99 | |
| Q3014 | Telehealth originating site facility fee | <1% | 184 | $269.93 |
| 84270 | <1% | 12 | $260.76 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 87 | $234.60 |
| 83002 | <1% | 12 | $222.24 | |
| 82533 | <1% | 13 | $211.90 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12 | $201.46 |
| 82150 | <1% | 44 | $188.98 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 65 | $173.17 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 37 | $165.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 647 | $158.94 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 30 | $152.00 |
| 86803 | <1% | 13 | $142.70 | |
| 82397 | <1% | 14 | $88.34 | |
| 83615 | <1% | 30 | $84.56 | |
| 99406 | <1% | 113 | $83.86 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 13 | $78.95 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 14 | $76.16 |
| 96376 | <1% | 108 | $64.30 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $60.75 |
| 85651 | <1% | 16 | $42.70 | |
| 86141 | <1% | 13 | $38.85 | |
| 85027 | <1% | 14 | $38.82 | |
| 85007 | <1% | 36 | $37.51 | |
| 1159F | <1% | 606 | $0.44 | |
| 1126F | <1% | 390 | $0.21 | |
| 3078F | <1% | 86 | $0.06 | |
| 96160 | <1% | 20 | $0.05 | |
| 1125F | <1% | 65 | $0.04 | |
| 1160F | <1% | 38 | $0.04 | |
| 3074F | <1% | 33 | $0.02 | |
| 1220F | <1% | 460 | $0.02 | |
| 3077F | <1% | 16 | $0.02 | |
| J2704 | Injection, propofol, 10 mg | 0% | 69 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 40 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 12 | $0.00 |
| 00000 | 0% | 371 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 41 | $0.00 |
| 91300 | 0% | 28 | $0.00 | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | 0% | 39 | $0.00 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCGRAW, STACEY (BUSINESS OFFICE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Riverside Medical Center | Franklinton, LA | $5.55M |
| Riverside Medical Center | Franklinton, LA | $894K |
| Riverside Medical Center | Franklinton, LA | $512K |
| Riverside Medical Center | Franklinton, LA | $102K |
| Riverside Medical Center | Franklinton, LA | $72K |
| Riverside Medical Center | Franklinton, LA | $7K |
| Riverside Medical Center | Franklinton, LA | $695.52 |
| Riverside Medical Center | Franklinton, LA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.